The identification of the HUB genes via the predicted interactions, also known as the interactome (Li, Sahni & Yi, 2016), is a powerful system-level approach that has been used in a variety of contexts to generate hypotheses and shape future research, including lung adenocarcinoma (Selamat et al., 2012), and prostate cancer (Song et al., 2019). Here, ELAVL2 is linked to prostate cancer.